World Health Organization (WHO) · Technical Documents

GRADE table: what ARV regimen to start with in adults, adolescents and pregnant women living with HIV-2?

World Health Organization
View original document

The full text is hosted by the publishing organisation. lawenc.com indexes the metadata and links to the official source.

Full text

WHO/HIV/2013.35

© World Health Organization 2013

GRADE tables: What ARV regimen to start with in adults, adolescents and pregnant women living with HIV-2? GRADE table (randomized trial), PI-based regimen versus three NRTIs among HIV-2 or dually reactive patients Quality assessment No. of studies Design No. of patients Effect Relative Absolute (95% CI) Quality Importance

Risk of bias Inconsistency Indirectness Imprecision Other considerations PI-based regimen Three NRTIs 0 0

Mortality (non-accidental deaths as a proportion of patients initiating ART) (observational) 0 Randomized trial CD4 cell increases measured at 24 weeks after ART initiation (observational) 0 Randomized trial

CRITICAL ⊕OOO VERY LOW CRITICAL ⊕OOO VERY LOW CRITICAL ⊕OOO VERY LOW CRITICAL ⊕OOO VERY LOW CRITICAL ⊕OOO VERY LOW CRITICAL ⊕OOO VERY LOW

0

0

-

-

0

Randomized trial

0

0

-

-

0

Randomized trial

0

0

-

-

0

Randomized trial

0

0

-

-

0

Randomized trial

0

0

-

-

References: none

This work was commissioned by the World Health Organization and carried out by Programme PACCI

1

WHO/HIV/2013.35

© World Health Organization 2013

GRADE table (observational studies), PI-based regimen versus three NRTIs among HIV-2 or dually reactive patients

Quality assessment No. of Risk of Other Design Inconsistency Indirectness Imprecision studies bias considerations Mortality (non-accidental deaths as a proportion of patients initiating ART) (observational) 7 observational very Very serious serious serious4 None studies serious CD4 cell increases measured at 24 weeks after ART initiation (observational) 6 observational very serious serious studies serious6 CD4 cell increases measured at 48 weeks after ART initiation (observational) 6 observational very serious serious studies serious6 Viral response at 48 weeks after ART initiation Very serious 5 observational very studies serious6

No. of patients PI-based Three Relative regimen NRTIs (95% CI) 30/697 (4.3%) Not estimated

Effect Quality Importance Absolute CRITICAL

⊕OOO VERY LOW ⊕OOO VERY LOW

very serious7

none

NA

NA

Not estimated

CRITICAL

very serious7

none

+102 –12.6 Not cells/mm3 cells/mm3 estimated

Mean difference9 +114 cells/mm3 higher

⊕OOO VERY LOW

CRITICAL

serious

very serious7

none

NA

NA

Not Mean difference –1.8 log10 ⊕OOO estimated HIV-2 RNA lower (62% VERY undetectable PI versus 17% LOW undetectable) Not estimated ⊕OOO VERY LOW ⊕OOO VERY LOW ⊕OOO VERY LOW

CRITICAL

Drug resistance (observational) 7 observational serious6 studies Adverse events 1 observational studies

serious inconsistency

no serious indirectness

very serious7

none

NA

NA

CRITICAL

serious6

serious inconsistency

no serious indirectness

very serious7

none

NA

NA

Not estimated

CRITICAL

Clinical progression to AIDS 3 observational serious6 studies

serious inconsistency

no serious indirectness

very serious7

none

NA

NA

Not estimated

CRITICAL

This work was commissioned by the World Health Organization and carried out by Programme PACCI

2

Key facts
Document type Technical Documents
Adoption date
Source World Health Organization